Form 4: Apellis Pharmaceuticals' Chief Medical Officer Reports Stock Transactions

Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, reports the sale of shares to cover tax withholding and the acquisition of restricted stock units.

Summary

• On January 17, 2025, Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, sold 1,853 shares of common stock at a price of $29.9582 per share.
• This sale was to cover tax withholding on restricted stock units released on January 16, 2025.
• On January 21, 2025, Ms. Baumal acquired 39,594 restricted stock units.
• These restricted stock units vest 25% annually over four years from the grant date, subject to continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected as part of executive compensation and tax obligations.

Positives

• The acquisition of 39,594 restricted stock units indicates a continued investment in the company's future by the Chief Medical Officer.

Future Outlook

The restricted stock units vest over four years, suggesting a long-term commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock transactions by executives are common in publicly traded companies, often involving the exercise of stock options or the vesting of restricted stock units.
• The vesting schedule of 25% annually over four years is a typical vesting arrangement for restricted stock units in the pharmaceutical industry.
• Comparing the size of the restricted stock unit award to those of executives at similar-sized pharmaceutical companies (e.g., Iveric Bio before its acquisition, or smaller biotechs like Annexon Biosciences) would provide context on the magnitude of the award.

Stakeholder Impact

• The stock sale has a minimal impact on shareholders as it is a small percentage of the total outstanding shares.
• The granting of restricted stock units aligns the executive's interests with those of the shareholders.

Key Dates